SG11202100054YA - Methods to reduce complications of intra-articular steroid - Google Patents

Methods to reduce complications of intra-articular steroid

Info

Publication number
SG11202100054YA
SG11202100054YA SG11202100054YA SG11202100054YA SG11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA
Authority
SG
Singapore
Prior art keywords
intra
methods
reduce complications
articular steroid
articular
Prior art date
Application number
SG11202100054YA
Inventor
Sheue-Fang Shih
Po-Chun Chang
Ming-Ju Wu
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of SG11202100054YA publication Critical patent/SG11202100054YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202100054YA 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid SG11202100054YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695763P 2018-07-09 2018-07-09
US201962839231P 2019-04-26 2019-04-26
PCT/US2019/040794 WO2020014118A1 (en) 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid

Publications (1)

Publication Number Publication Date
SG11202100054YA true SG11202100054YA (en) 2021-02-25

Family

ID=67441711

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100054YA SG11202100054YA (en) 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid

Country Status (10)

Country Link
US (1) US12083138B2 (en)
EP (1) EP3820479A1 (en)
JP (1) JP7463306B2 (en)
KR (1) KR20210031715A (en)
CN (1) CN112469420A (en)
AU (1) AU2019301542A1 (en)
BR (1) BR112021000316A2 (en)
CA (1) CA3105743A1 (en)
SG (1) SG11202100054YA (en)
WO (1) WO2020014118A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230057155A1 (en) * 2021-08-11 2023-02-23 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE10255106A1 (en) * 2002-11-24 2004-06-09 Novosom Ag Liposomal glucocorticoids
US20130296267A1 (en) 2008-01-18 2013-11-07 Horst Kief Agent for intra-articular injection
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
UA111162C2 (en) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. INJECTION COMPOSITION OF TRIAMCINOLONE ACETONIDE FOR TREATMENT OF PAIN
RU2660585C2 (en) 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Pharmaceutical compositions to reduce complications of ocular steroid
SG11201408810TA (en) 2012-07-05 2015-01-29 Taiwan Liposome Co Ltd Methods of treating arthritis
TWI674899B (en) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 Pharmaceutical formulation

Also Published As

Publication number Publication date
JP7463306B2 (en) 2024-04-08
EP3820479A1 (en) 2021-05-19
US20210196733A1 (en) 2021-07-01
CA3105743A1 (en) 2020-01-16
BR112021000316A2 (en) 2021-04-06
WO2020014118A1 (en) 2020-01-16
KR20210031715A (en) 2021-03-22
US12083138B2 (en) 2024-09-10
TW202007398A (en) 2020-02-16
AU2019301542A1 (en) 2021-02-25
JP2021532074A (en) 2021-11-25
CN112469420A (en) 2021-03-09

Similar Documents

Publication Publication Date Title
IL289046A (en) Compositions and methods for inhibition of lineage specific antigens
IL268895A (en) Compositions and methods for inhibition of lineage specific proteins
EP3355895A4 (en) Crystal forms of beta-nicotinamide mononucleotide
EP3370518A4 (en) Compositions and methods for reducing ice crystal formation
EP3250211A4 (en) Novel process for preparation of glucocorticoid steroids
EP3233047A4 (en) Compositions and methods for improving the appearance of the skin
EP3229997A4 (en) Additive manufacturing of metallic structures
EP3242672A4 (en) Amnion derived therapeutic composition and process of making same
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
EP3102673A4 (en) Methods and compositions for treatment of a beta thalessemia
PT3221331T (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
PL3221332T3 (en) 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
EP3206705A4 (en) Stable injectable composition of bivalirudin and process for its preparation
EP3279181A4 (en) Mixture of polymerizable compound and method for producing same
MX2015016031A (en) Processes for the preparation of dehydroepiandrosterone and its intermediates.
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
EP3215132A4 (en) Methods of administering amantadine compositions
EP3504221A4 (en) Novel process for preparation of corticosteroids
PT3368673T (en) Compositions and methods for production of myrcene
EP3215140A4 (en) Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3352738A4 (en) Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients
EP3221351A4 (en) Methods and compositions for cancer treating conditions relating to over expressions of epha2
EP3504178A4 (en) Compositions and methods related to the production of acrylonitrile
EP3703742A4 (en) Methods and compositions related to increased rotavirus production
EP3618869A4 (en) COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES